Evidence map›Paper›PMID 39250109›Full record

ArticleDiabetes care2025

Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Glucose-Lowering Medication Under Conditions of Clinical Uncertainty.

James H Flory, Jessica S Ancker, Scott Y H Kim, Gilad Kuperman, Aleksandr Petrov, Andrew Vickers

Abstract read
In one paragraph

Article in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

James H FloryMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0259-969X
Jessica S AnckerVanderbilt University Medical Center, Nashville, TN.
Scott Y H KimNational Institutes of Health, Bethesda, MD.
Gilad KupermanMemorial Sloan Kettering Cancer Center, New York, NY.
Aleksandr PetrovMemorial Sloan Kettering Cancer Center, New York, NY.
Andrew VickersMemorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4M
National Institutes of Health/National Cancer Institute (NIH/NCI)NCI NIH HHS P30 CA008748Patient Centered Outcomes Research Institute CER-2017C3-9230
6 · The paper itself

Abstract

objectiveTo explore how the commercially available large language model (LLM) GPT-4 compares to endocrinologists when addressing medical questions when there is uncertainty regarding the best answer. RESEARCH DESIGN AND

methodsThis study compared responses from GPT-4 to responses from 31 endocrinologists using hypothetical clinical vignettes focused on diabetes, specifically examining the prescription of metformin versus alternative treatments. The primary outcome was the choice between metformin and other treatments.

resultsWith a simple prompt, GPT-4 chose metformin in 12% (95% CI 7.9-17%) of responses, compared with 31% (95% CI 23-39%) of endocrinologist responses. After modifying the prompt to encourage metformin use, the selection of metformin by GPT-4 increased to 25% (95% CI 22-28%). GPT-4 rarely selected metformin in patients with impaired kidney function, or a history of gastrointestinal distress (2.9% of responses, 95% CI 1.4-5.5%). In contrast, endocrinologists often prescribed metformin even in patients with a history of gastrointestinal distress (21% of responses, 95% CI 12-36%). GPT-4 responses showed low variability on repeated runs except at intermediate levels of kidney function.

conclusionsIn clinical scenarios with no single right answer, GPT-4's responses were reasonable, but differed from endocrinologists' responses in clinically important ways. Value judgments are needed to determine when these differences should be addressed by adjusting the model. We recommend against reliance on LLM output until it is shown to align not just with clinical guidelines but also with patient and clinician preferences, or it demonstrates improvement in clinical outcomes over standard of care.

Indexed as

EndocrinologistsHypoglycemic AgentsAdultDiabetes Mellitus, Type 2FemaleHumansLarge Language ModelsMaleMetforminMiddle AgedUncertaintyHypoglycemic AgentsMetformin

Identifiers

PMID39250109
PMCPMC11770168

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.